It was a pleasure to be able to catch up with Dr Esther van Zuuren (Leiden University Medical Centre, Leiden, the Netherlands) to discuss rosacea classification and how this can impact treatment choices.
Her presentation entitled ‘Update on topical drugs in rosacea‘ was received at the EADV Spring Symposium, 6-7 May 2021.
- Could you give us an overview of the incidence of rosacea? (0:05)
- Can you tell us about the classification of rosacea and how it has changed? (start 1:08)
- How do these features impact treatment choices and what should we be considering? (3:39)
Disclosures: Dr Esther van Zuuren has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed as a highlight of EADV Spring Symposium 2021 (Virtual).
Share this Video
Related Videos In Dermatological Conditions
Sonja Ständer, EADV 2021: New Therapies for Chronic Pruritus and Prurigo
touchIMMUNOLOGY had the great pleasure of speaking with Prof. Sonja Ständer (University Hospital Münster, Münster, Germany) about new treatments for chronic pruritus and prurigo. Her presentation entitled ‘New treatments for chronic pruritus and prurigo’ was given at the EADV 30th Congress, 29 Sep – 2 Oct. Disclosures: Prof. Sonja Ständer has acted as an investigator […]
Sonja Ständer, EADV 2021: Nemolizumab in the Treatment of Prurigo Nodularis
Prof. Sonja Ständer (University Hospital Münster, Münster, Germany) kindly took the time to speak to us about the health burden of prurigo and recent investigations into the IL-31 targeted therapy, nemolizumab. Her presentation entitled ‘Nemolizumab rapidly relieves itch and sleep disturbances in patients with prurigo nodularis’ was given at the EADV 30th Congress, 29 Sep […]
Sorena Kiani, EAACI 2021: Berotralstat in the Treatment of Hereditary Angioedema
touchIMMUNOLOGY joins Dr Sorena Kiani (Barts Health NHS Trust, London, UK) to discuss the efficacy and safety of berotralstat in the treatment of hereditary angioedema. Questions 1. What are the unmet needs in the treatment of hereditary angioedema (HAE)? (00:17-01:53) 2. What is berotralstat and what is the rationale for its use in HAE? (01:53-03:17) […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!